Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection  Yoav Lurie, Regine Rouzier-Panis, George.

Slides:



Advertisements
Similar presentations
Celiac Disease Genetics: Current Concepts and Practical Applications Ludvig M. Sollid, Benedicte A. Lie Clinical Gastroenterology and Hepatology Volume.
Advertisements

Masatoshi Kudo  Clinical Gastroenterology and Hepatology 
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection 
Volume 139, Issue 4, Pages (October 2010)
The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting  Adnan Said, John Williams, Jeremy Holden,
Noncardiac Chest Pain Clinical Gastroenterology and Hepatology
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Volume 44, Issue 4, Pages (April 2006)
Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Volume 139, Issue 4, Pages (October 2010)
The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting  Adnan Said, John Williams, Jeremy Holden,
Virological tools to diagnose and monitor hepatitis C virus infection
Michael Biermer, Thomas Berg  Gastroenterology 
Evaluation and Treatment of Obesity
Short-Bowel Syndrome Clinical Gastroenterology and Hepatology
Diagnosing autoimmune hepatitis in children: Is the International Autoimmune Hepatitis Group scoring system useful?  Regan L. Ebbeson, Richard A. Schreiber 
Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse 
Yasuhiko Sugawara, Masatoshi Makuuchi 
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome  Onur Keskin, Heiner Wedemeyer, Ali Tüzün, Kalliopi.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C  Pamela S. Belperio, Elizabeth.
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay?  Brian J. McMahon, MD, Brenna C. Simons, PhD  Clinical.
Acute hepatitis C: Current status and remaining challenges
Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
Michael Charlton  Clinical Gastroenterology and Hepatology 
Anouk Dev, Keyur Patel, Andrew Conrad, Lawrence M. Blatt, John G
Validation of Hepascore, Compared With Simple Indices of Fibrosis, in Patients With Chronic Hepatitis C Virus Infection in United States  Laren Becker,
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Severe Constipation Clinical Gastroenterology and Hepatology
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek 
Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients  Vincent G. Bain, Kelly D.
Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C  David R. Nelson, Vinod Rustgi, Vijayan.
Effect of Human Immunodeficiency Virus and Antiretrovirals on Outcomes of Hepatitis C: A Systematic Review From an Epidemiologic Perspective  Jennifer.
Volume 138, Issue 1, Pages e2 (January 2010)
Chronic Hepatitis C Therapy: Changing the Rules of Duration
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Brendan Campbell, Benny Liu, Taft Bhuket, Robert J. Wong 
Volume 132, Issue 1, Pages 5-6 (January 2007)
Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg 
Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6
Anil T. George, Raman V. Nair  Clinical Gastroenterology and Hepatology 
Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin?  Lawrence.
Esophageal variceal bleeding: Primary prophylaxis
Alan Bonder, MD, Nezam H. Afdhal, MD 
Chronic Diarrhea Clinical Gastroenterology and Hepatology
Hepatitis C treatment in patients with kidney disease
Christos Konstantakis, Maria Karamesini, Christos Triantos 
Severe irritable bowel and functional abdominal pain syndromes: Managing the patient and health care costs  George F. Longstreth, Douglas A. Drossman 
Volume 125, Issue 6, Pages (December 2003)
Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels  Mitchell L. Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert.
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States  Zobair M. Younossi, Maria Stepanova 
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Volume 156, Issue 3, Pages (February 2019)
Julia Lörke, Andreas Erhardt, Dieter Häussinger 
Novel Therapies for Hepatitis C Virus Based on Lessons From Virology
Clinical Gastroenterology and Hepatology
Masatoshi Kudo  Clinical Gastroenterology and Hepatology 
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Kathleen E. Corey, Andrew S
Medical Therapy for Refractory Pediatric Crohn’s Disease
Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,
Presentation transcript:

Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection  Yoav Lurie, Regine Rouzier-Panis, George J.M. Webster, Geoffrey M. Dusheiko, Mark Laughlin, Mary L. Jackson, Ran Oren  Clinical Gastroenterology and Hepatology  Volume 3, Issue 6, Pages 610-615 (June 2005) DOI: 10.1016/S1542-3565(04)00723-2 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Effect of PEG-IFN-alfa2b dosage on HCV-RNA clearance at week 12. Bars are mean values with standard error (*#x002A;P < .05 vs IFN-alfa2b). BIW, 2 times/wk; QW, 1 time/wk; TIW, 3 times/wk. Clinical Gastroenterology and Hepatology 2005 3, 610-615DOI: (10.1016/S1542-3565(04)00723-2) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Decrease in absolute neutrophil count (109 cells/L) by dose regimen, from treatment initiation through week 12. BIW, 2 times/wk; QW, 1 time/wk; TIW, 3 times/wk. Clinical Gastroenterology and Hepatology 2005 3, 610-615DOI: (10.1016/S1542-3565(04)00723-2) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.